Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Edward H. Romond, M.D., Edith A. Perez, M.D., John Bryant, Ph.D., Vera J. Suman, Ph.D., Charles E. Geyer, Jr., M.D., Nancy E. Davidson, M.D., Elizabeth Tan-Chiu, M.D., Silvana Martino, D.O., Soonmyung Paik, M.D., Peter A. Kaufman, M.D., Sandra M. Swain, M.D., Thomas M. Pisansky, M.D., Louis Fehrenbacher, M.D., Leila A. Kutteh, M.D., Victor G. Vogel, M.D., Daniel W. Visscher, M.D., Greg Yothers, Ph.D., Robert B. Jenkins, M.D., Ph.D., Ann M. Brown, Sc.D., Shaker R. Dakhil, M.D., Eleftherios P. Mamounas, M.D., M.P.H., Wilma L. Lingle, Ph.D., Pamela M. Klein, M.D., James N. Ingle, M.D., and Norman Wolmark, M.D.
Background We present the combined results of two trials thatcompared adjuvant chemotherapy with or without concurrent trastuzumabin women with surgically removed HER2-positive breast cancer.
Methods The National Surgical Adjuvant Breast and Bowel Projecttrial B-31 compared doxorubicin and cyclophosphamide followedby paclitaxel every 3 weeks (group 1) with the same regimenplus 52 weeks of trastuzumab beginning with the first dose ofpaclitaxel (group 2). The North Central Cancer Treatment Grouptrial N9831 compared three regimens: doxorubicin and cyclophosphamidefollowed by weekly paclitaxel (group A), the same regimen followedby 52 weeks of trastuzumab after paclitaxel (group B), and thesame regimen plus 52 weeks of trastuzumab initiated concomitantlywith paclitaxel (group C). The studies were amended to includea joint analysis comparing groups 1 and A (the control group)with groups 2 and C (the trastuzumab group). Group B was excludedbecause trastuzumab was not given concurrently with paclitaxel.
Results By March 15, 2005, 394 events (recurrent, second primarycancer, or death before recurrence) had been reported, triggeringthe first scheduled interim analysis. Of these, 133 were inthe trastuzumab group and 261 in the control group (hazard ratio,0.48; P<0.0001). This result crossed the early stopping boundary.The absolute difference in disease-free survival between thetrastuzumab group and the control group was 12 percent at threeyears. Trastuzumab therapy was associated with a 33 percentreduction in the risk of death (P=0.015). The three-year cumulativeincidence of class III or IV congestive heart failure or deathfrom cardiac causes in the trastuzumab group was 4.1 percentin trial B-31 and 2.9 percent in trial N9831.
Conclusions Trastuzumab combined with paclitaxel after doxorubicinand cyclophosphamide improves outcomes among women with surgicallyremoved HER2-positive breast cancer. (ClinicalTrials.gov numbers,NCT00004067
[ClinicalTrials.gov]
and NCT00005970
[ClinicalTrials.gov]
.)
Source Information
From the National Surgical Adjuvant Breast and Bowel Project, Pittsburgh (E.H.R., J.B., C.E.G., E.T.-C., S.P., S.M.S., L.F., V.G.V., G.Y., A.M.B., E.P.M., N.W.); University of Kentucky, Lexington (E.H.R.); North Central Cancer Treatment Group, Rochester, Minn. (E.A.P., V.J.S., T.M.P., L.A.K., D.W.V., R.B.J., S.R.D., W.L.L., J.N.I.); Mayo Clinic Jacksonville, Jacksonville, Fla. (E.A.P.); University of Pittsburgh, Pittsburgh (J.B., G.Y.); Mayo Clinic, Rochester, Minn. (V.J.S., T.M.P., D.W.V., R.B.J., W.L.L., J.N.I.); Allegheny General Hospital, Pittsburgh (C.E.G., N.W.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (N.E.D.), the Cancer Research Network, Plantation, Fla. (E.T.-C.); Angeles Clinic and Research Institute, Santa Monica, Calif. (S.M.); Norris Cotton Cancer Center, Dartmouth–Hitchcock Medical Center, Lebanon, N.H. (P.A.K.); Cancer Therapeutics Branch, National Cancer Institute, Bethesda, Md. (S.M.S.); Kaiser Permanente Medical Center Northern California, Vallejo (L.F.); Oncology Associates of Cedar Rapids, Cedar Rapids, Iowa (L.A.K.); University of Pittsburgh Cancer Institute, Pittsburgh (V.G.V.); Wichita Community Clinical Oncology Program, Wichita, Kans. (S.R.D.); Aultman Health Foundation, Canton, Ohio (E.P.M.); and Genentech, South San Francisco, Calif. (P.M.K.). Drs. Romond and Perez contributed equally to the article.
Address reprint requests to Dr. Geyer at the Allegheny Cancer Center, 5th Fl., 320 E. North Ave., Pittsburgh, PA 15212, or at cgeyer{at}wpahs.org.
Trastuzumab in Breast Cancer
Gilbert S. G., Banna G. L., Santoro A., Gounaris I. G., Katsumata M., Drebin J. A., Greene M. I., Mastrianni D. M., Mano M., Cameron D., Gelber R. D., the HERA Trial Study Team , Bryant J., Romond E., Perez E. A., Hortobagyi G. N., Barron H.
Extract |
Full Text |
PDF
N Engl J Med 2006;
354:640-644, Feb 9, 2006.
Correspondence
This article has been cited by other articles:
Kataoka, Y., Mukohara, T., Shimada, H., Saijo, N., Hirai, M., Minami, H.
(2010). Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol
21: 255-262
[Abstract][Full Text]
De Keulenaer, G. W., Doggen, K., Lemmens, K.
(2010). The Vulnerability of the Heart As a Pluricellular Paracrine Organ: Lessons From Unexpected Triggers of Heart Failure in Targeted ErbB2 Anticancer Therapy. Circ. Res.
106: 35-46
[Abstract][Full Text]
Dawood, S., Broglio, K., Buzdar, A. U., Hortobagyi, G. N., Giordano, S. H.
(2010). Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review. JCO
28: 92-98
[Abstract][Full Text]
Morris, P. G., Dickler, M., McArthur, H. L., Traina, T., Sugarman, S., Lin, N., Moy, B., Come, S., Godfrey, L., Nulsen, B., Chen, C., Steingart, R., Rugo, H., Norton, L., Winer, E., Hudis, C. A., Dang, C. T.
(2009). Dose-Dense Adjuvant Doxorubicin and Cyclophosphamide Is Not Associated With Frequent Short-Term Changes in Left Ventricular Ejection Fraction. JCO
27: 6117-6123
[Abstract][Full Text]
Spielmann, M., Roche, H., Delozier, T., Canon, J.-L., Romieu, G., Bourgeois, H., Extra, J.-M., Serin, D., Kerbrat, P., Machiels, J.-P., Lortholary, A., Orfeuvre, H., Campone, M., Hardy-Bessard, A.-C., Coudert, B., Maerevoet, M., Piot, G., Kramar, A., Martin, A.-L., Penault-Llorca, F.
(2009). Trastuzumab for Patients With Axillary-Node-Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial. JCO
27: 6129-6134
[Abstract][Full Text]
Scheuer, W., Friess, T., Burtscher, H., Bossenmaier, B., Endl, J., Hasmann, M.
(2009). Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models. Cancer Res.
69: 9330-9336
[Abstract][Full Text]
Pohlmann, P. R., Mayer, I. A., Mernaugh, R.
(2009). Resistance to Trastuzumab in Breast Cancer. Clin. Cancer Res.
15: 7479-7491
[Abstract][Full Text]
Sparano, J. A., Goldstein, L. J., Childs, B. H., Shak, S., Brassard, D., Badve, S., Baehner, F. L., Bugarini, R., Rowley, S., Perez, E., Shulman, L. N., Martino, S., Davidson, N. E., Sledge, G. W. Jr., Gray, R.
(2009). Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin. Cancer Res.
15: 7693-7700
[Abstract][Full Text]
Joensuu, H., Bono, P., Kataja, V., Alanko, T., Kokko, R., Asola, R., Utriainen, T., Turpeenniemi-Hujanen, T., Jyrkkio, S., Moykkynen, K., Helle, L., Ingalsuo, S., Pajunen, M., Huusko, M., Salminen, T., Auvinen, P., Leinonen, H., Leinonen, M., Isola, J., Kellokumpu-Lehtinen, P.-L.
(2009). Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial. JCO
27: 5685-5692
[Abstract][Full Text]
Curigliano, G., Viale, G., Bagnardi, V., Fumagalli, L., Locatelli, M., Rotmensz, N., Ghisini, R., Colleoni, M., Munzone, E., Veronesi, P., Zurrida, S., Nole, F., Goldhirsch, A.
(2009). Clinical Relevance of HER2 Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer. JCO
27: 5693-5699
[Abstract][Full Text]
Spector, N. L., Blackwell, K. L.
(2009). Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. JCO
27: 5838-5847
[Abstract][Full Text]
Gonzalez-Angulo, A. M., Litton, J. K., Broglio, K. R., Meric-Bernstam, F., Rakkhit, R., Cardoso, F., Peintinger, F., Hanrahan, E. O., Sahin, A., Guray, M., Larsimont, D., Feoli, F., Stranzl, H., Buchholz, T. A., Valero, V., Theriault, R., Piccart-Gebhart, M., Ravdin, P. M., Berry, D. A., Hortobagyi, G. N.
(2009). High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2-Positive, Node-Negative Tumors 1 cm or Smaller. JCO
27: 5700-5706
[Abstract][Full Text]
Burstein, H. J., Winer, E. P.
(2009). Refining Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: T Stands for Trastuzumab, Tumor Size, and Treatment Strategy. JCO
27: 5671-5673
[Full Text]
Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U., Harbeck, N.
(2009). Triple-negative breast cancer--current status and future directions. Ann Oncol
20: 1913-1927
[Abstract][Full Text]
Mittendorf, E. A., Wu, Y., Scaltriti, M., Meric-Bernstam, F., Hunt, K. K., Dawood, S., Esteva, F. J., Buzdar, A. U., Chen, H., Eksambi, S., Hortobagyi, G. N., Baselga, J., Gonzalez-Angulo, A. M.
(2009). Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes. Clin. Cancer Res.
15: 7381-7388
[Abstract][Full Text]
Miller, T. W., Forbes, J. T., Shah, C., Wyatt, S. K., Manning, H. C., Olivares, M. G., Sanchez, V., Dugger, T. C., de Matos Granja, N., Narasanna, A., Cook, R. S., Kennedy, J. P., Lindsley, C. W., Arteaga, C. L.
(2009). Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells. Clin. Cancer Res.
15: 7266-7276
[Abstract][Full Text]
Damiano, V., Garofalo, S., Rosa, R., Bianco, R., Caputo, R., Gelardi, T., Merola, G., Racioppi, L., Garbi, C., Kandimalla, E. R., Agrawal, S., Tortora, G.
(2009). A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action. Clin. Cancer Res.
15: 6921-6930
[Abstract][Full Text]
Lae, M., Couturier, J., Oudard, S., Radvanyi, F., Beuzeboc, P., Vieillefond, A.
(2009). Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol
0: mdp488v1-mdp488
[Abstract][Full Text]
Taube, S. E., Clark, G. M., Dancey, J. E., McShane, L. M., Sigman, C. C., Gutman, S. I.
(2009). A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment. JNCI J Natl Cancer Inst
101: 1453-1463
[Abstract][Full Text]
Kaumaya, P. T.P., Foy, K. C., Garrett, J., Rawale, S. V., Vicari, D., Thurmond, J. M., Lamb, T., Mani, A., Kane, Y., Balint, C. R., Chalupa, D., Otterson, G. A., Shapiro, C. L., Fowler, J. M., Grever, M. R., Bekaii-Saab, T. S., Carson, W. E. III
(2009). Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors. JCO
27: 5270-5277
[Abstract][Full Text]
Leyland-Jones, B.
(2009). Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Central Nervous System Metastases. JCO
27: 5278-5286
[Abstract][Full Text]
Green, M. D., Francis, P. A., Gebski, V., Harvey, V., Karapetis, C., Chan, A., Snyder, R., Fong, A., Basser, R., Forbes, J. F., on behalf of the Australian New Zealand Breast Can,
(2009). Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Ann Oncol
20: 1813-1817
[Abstract][Full Text]
Roy, V., Perez, E. A.
(2009). Beyond Trastuzumab: Small Molecule Tyrosine Kinase Inhibitors in HER-2-Positive Breast Cancer. The Oncologist
14: 1061-1069
[Abstract][Full Text]
Hammond, E. H., Wolff, A. C., Hayes, D. F., Schwartz, J. N.
(2009). Reply to G. Sauter et al. JCO
27: e153-e154
[Full Text]
Reim, F., Dombrowski, Y., Ritter, C., Buttmann, M., Hausler, S., Ossadnik, M., Krockenberger, M., Beier, D., Beier, C. P., Dietl, J., Becker, J. C., Honig, A., Wischhusen, J.
(2009). Immunoselection of Breast and Ovarian Cancer Cells with Trastuzumab and Natural Killer Cells: Selective Escape of CD44high/CD24low/HER2low Breast Cancer Stem Cells. Cancer Res.
69: 8058-8066
[Abstract][Full Text]
McArthur, H. L., Hudis, C. A.
(2009). Trastuzumab: A Picky Partner?. Clin. Cancer Res.
15: 6311-6313
[Abstract][Full Text]
Zhao, J. J., Silver, D. P.
(2009). Estrogen Receptor-Negative Breast Cancer: New Insights into Subclassification and Targeting. Clin. Cancer Res.
15: 6309-6310
[Abstract][Full Text]
Kwan, W., Al-Tourah, A. J., Speers, C., Woods, R., Kennecke, H., Olivotto, I. A.
(2009). Does HER2 status influence locoregional failure rates in breast cancer patients treated with mastectomy for pT1-2pN0 disease?. Ann Oncol
0: mdp396v1-mdp396
[Abstract][Full Text]
Penault-Llorca, F., Bilous, M., Dowsett, M., Hanna, W., Osamura, R. Y., Ruschoff, J., van de Vijver, M.
(2009). Emerging Technologies for Assessing HER2 Amplification. Am J Clin Pathol
132: 539-548
[Abstract][Full Text]
Gianni, L., Norton, L., Wolmark, N., Suter, T. M., Bonadonna, G., Hortobagyi, G. N.
(2009). Role of Anthracyclines in the Treatment of Early Breast Cancer. JCO
27: 4798-4808
[Abstract][Full Text]
Sikov, W. M., Dizon, D. S., Strenger, R., Legare, R. D., Theall, K. P., Graves, T. A., Gass, J. S., Kennedy, T. A., Fenton, M. A.
(2009). Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study. JCO
27: 4693-4700
[Abstract][Full Text]
VAN ROOIJ, F. G., DORRESTEIJN, L. D.A., VAN BOKHOVEN, M. M.J.A., VERSTAPPEN, C. C.P.
(2009). A Throbbing Pain in the Head: Trastuzumab-induced Migraine. Anticancer Res
29: 4223-4225
[Abstract][Full Text]
Robson, D., Verma, S.
(2009). Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era?. The Oncologist
14: 950-958
[Abstract][Full Text]
Normanno, N., Morabito, A., De Luca, A., Piccirillo, M. C., Gallo, M., Maiello, M. R, Perrone, F.
(2009). Target-based therapies in breast cancer: current status and future perspectives. Endocr Relat Cancer
16: 675-702
[Abstract][Full Text]
Hurria, A., Wong, F. L., Pal, S., Chung, C. T., Bhatia, S., Mortimer, J., Somlo, G., Hurvitz, S., Villaluna, D., Naeim, A.
(2009). Perspectives and Attitudes on the Use of Adjuvant Chemotherapy and Trastuzumab in Older Adults with HER-2+ Breast Cancer: A Survey of Oncologists. The Oncologist
14: 883-890
[Abstract][Full Text]
Pienkowski, T., Zielinski, C. C.
(2009). Trastuzumab treatment in patients with breast cancer and metastatic CNS disease. Ann Oncol
0: mdp353v1-mdp353
[Abstract][Full Text]
Mandrekar, S. J., Sargent, D. J.
(2009). Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges. JCO
27: 4027-4034
[Abstract][Full Text]
Faratian, D., Goltsov, A., Lebedeva, G., Sorokin, A., Moodie, S., Mullen, P., Kay, C., Um, I. H., Langdon, S., Goryanin, I., Harrison, D. J.
(2009). Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab. Cancer Res.
69: 6713-6720
[Abstract][Full Text]
Fojo, T., Grady, C.
(2009). How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. JNCI J Natl Cancer Inst
101: 1044-1048
[Abstract][Full Text]
Gong, Y., Sweet, W., Duh, Y.-J., Greenfield, L., Tarco, E., Trivedi, S., Symmans, W. F., Isola, J., Sneige, N.
(2009). Performance of Chromogenic In Situ Hybridization on Testing HER2 Status in Breast Carcinomas With Chromosome 17 Polysomy and Equivocal (2+) HercepTest Results: A Study of Two Institutions Using the Conventional and New ASCO/CAP Scoring Criteria. Am J Clin Pathol
132: 228-236
[Abstract][Full Text]
Shimizu, C., Masuda, N., Yoshimura, K., Tsuda, H., Mano, M., Ando, M., Tamura, K., Fujiwara, Y.
(2009). Long-term Outcome and Pattern of Relapse after Neoadjuvant Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 2-positive Primary Breast Cancer. Jpn J Clin Oncol
39: 484-490
[Abstract][Full Text]
Takabatake, D., Taira, N., Hara, F., Sien, T., Kiyoto, S., Takashima, S., Aogi, K., Ohsumi, S., Doihara, H., Takashima, S.
(2009). Feasibility Study of Docetaxel with Cyclophosphamide as Adjuvant Chemotherapy for Japanese Breast Cancer Patients. Jpn J Clin Oncol
39: 478-483
[Abstract][Full Text]
Correa Geyer, F., Reis-Filho, J. S.
(2009). Microarray-based Gene Expression Profiling as a Clinical Tool for Breast Cancer Management: Are We There Yet?. INT J SURG PATHOL
17: 285-302
[Abstract]
Choi, Y. H., Ahn, J. H., Kim, S.-B., Jung, K.-H., Gong, G.-Y., Kim, M.-J., Son, B.-H., Ahn, S.-H., Kim, W. K.
(2009). Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis. Ann Oncol
20: 1337-1343
[Abstract][Full Text]
Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thurlimann, B., Senn, H.-J., Panel members,
(2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol
20: 1319-1329
[Abstract][Full Text]
Mitra, D., Brumlik, M. J., Okamgba, S. U., Zhu, Y., Duplessis, T. T., Parvani, J. G., Lesko, S. M., Brogi, E., Jones, F. E.
(2009). An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Molecular Cancer Therapeutics
8: 2152-2162
[Abstract][Full Text]
Haykowsky, M. J., Mackey, J. R., Thompson, R. B., Jones, L. W., Paterson, D. I.
(2009). Adjuvant Trastuzumab Induces Ventricular Remodeling Despite Aerobic Exercise Training. Clin. Cancer Res.
15: 4963-4967
[Abstract][Full Text]
Barron, J. J., Cziraky, M. J., Weisman, T., Hicks, D. G.
(2009). HER2 Testing and Subsequent Trastuzumab Treatment for Breast Cancer in a Managed Care Environment. The Oncologist
14: 760-768
[Abstract][Full Text]
Shi, L., Dong, B., Li, Z., Lu, Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., Wang, Z., Xie, Y.
(2009). Expression of ER-{alpha}36, a Novel Variant of Estrogen Receptor {alpha}, and Resistance to Tamoxifen Treatment in Breast Cancer. JCO
27: 3423-3429
[Abstract][Full Text]
Guarneri, V., Conte, P.
(2009). Metastatic Breast Cancer: Therapeutic Options According to Molecular Subtypes and Prior Adjuvant Therapy. The Oncologist
14: 645-656
[Abstract][Full Text]
Rhodes, D. R., Ateeq, B., Cao, Q., Tomlins, S. A., Mehra, R., Laxman, B., Kalyana-Sundaram, S., Lonigro, R. J., Helgeson, B. E., Bhojani, M. S., Rehemtulla, A., Kleer, C. G., Hayes, D. F., Lucas, P. C., Varambally, S., Chinnaiyan, A. M.
(2009). AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc. Natl. Acad. Sci. USA
106: 10284-10289
[Abstract][Full Text]
Dowsett, M., Procter, M., McCaskill-Stevens, W., de Azambuja, E., Dafni, U., Rueschoff, J., Jordan, B., Dolci, S., Abramovitz, M., Stoss, O., Viale, G., Gelber, R. D., Piccart-Gebhart, M., Leyland-Jones, B.
(2009). Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial. JCO
27: 2962-2969
[Abstract][Full Text]
Yeh, E. T.H., Bickford, C. L.
(2009). Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.. J Am Coll Cardiol
53: 2231-2247
[Abstract][Full Text]
Halyard, M. Y., Pisansky, T. M., Dueck, A. C., Suman, V., Pierce, L., Solin, L., Marks, L., Davidson, N., Martino, S., Kaufman, P., Kutteh, L., Dakhil, S. R., Perez, E. A.
(2009). Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831. JCO
27: 2638-2644
[Abstract][Full Text]
Onitilo, A. A., Engel, J. M., Greenlee, R. T., Mukesh, B. N.
(2009). Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival. Clin Med Res
7: 4-13
[Abstract][Full Text]
Buzdar, A. U.
(2009). Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. Ann Oncol
20: 993-999
[Abstract][Full Text]
Quaye, L., Dafou, D., Ramus, S. J., Song, H., Maharaj, A. G., Notaridou, M., Hogdall, E., Kjaer, S. K., Christensen, L., Hogdall, C., Easton, D. F., Jacobs, I., Menon, U., Pharoah, P. D.P., Gayther, S. A.
(2009). Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. Hum Mol Genet
18: 1869-1878
[Abstract][Full Text]
Hennessy, B. T., Gonzalez-Angulo, A.-M., Stemke-Hale, K., Gilcrease, M. Z., Krishnamurthy, S., Lee, J.-S., Fridlyand, J., Sahin, A., Agarwal, R., Joy, C., Liu, W., Stivers, D., Baggerly, K., Carey, M., Lluch, A., Monteagudo, C., He, X., Weigman, V., Fan, C., Palazzo, J., Hortobagyi, G. N., Nolden, L. K., Wang, N. J., Valero, V., Gray, J. W., Perou, C. M., Mills, G. B.
(2009). Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics. Cancer Res.
69: 4116-4124
[Abstract][Full Text]
Baar, J., Silverman, P., Lyons, J., Fu, P., Abdul-Karim, F., Ziats, N., Wasman, J., Hartman, P., Jesberger, J., Dumadag, L., Hohler, E., Leeming, R., Shenk, R., Chen, H., McCrae, K., Dowlati, A., Remick, S. C., Overmoyer, B.
(2009). A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers. Clin. Cancer Res.
15: 3583-3590
[Abstract][Full Text]
Rickman, O. B., Vohra, P. K., Sanyal, B., Vrana, J. A., Aubry, M.-C., Wigle, D. A., Thomas, C. F. Jr.
(2009). Analysis of ErbB Receptors in Pulmonary Carcinoid Tumors. Clin. Cancer Res.
15: 3315-3324
[Abstract][Full Text]
Shulman, L. N., Jacobs, L. A., Greenfield, S., Jones, B., McCabe, M. S., Syrjala, K., Diller, L., Shapiro, C. L., Marcus, A. C., Campbell, M., Santacroce, S., Kagawa-Singer, M., Ganz, P. A.
(2009). Cancer Care and Cancer Survivorship Care in the United States: Will We Be Able to Care for These Patients in the Future?. J Oncol Pract
5: 119-123
[Abstract][Full Text]
Xenidis, N., Ignatiadis, M., Apostolaki, S., Perraki, M., Kalbakis, K., Agelaki, S., Stathopoulos, E. N., Chlouverakis, G., Lianidou, E., Kakolyris, S., Georgoulias, V., Mavroudis, D.
(2009). Cytokeratin-19 mRNA-Positive Circulating Tumor Cells After Adjuvant Chemotherapy in Patients With Early Breast Cancer. JCO
27: 2177-2184
[Abstract][Full Text]
Barrett-Lee, P. J., Dixon, J. M., Farrell, C., Jones, A., Leonard, R., Murray, N., Palmieri, C., Plummer, C. J., Stanley, A., Verrill, M. W.
(2009). Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol
20: 816-827
[Abstract][Full Text]
BROOM, R. J., TANG, P. A., SIMMONS, C., BORDELEAU, L., MULLIGAN, A. M., O'MALLEY, F. P., MILLER, N., ANDRULIS, I. L., BRENNER, D. M., CLEMONS, M. J.
(2009). Changes in Estrogen Receptor, Progesterone Receptor and Her-2/neu Status with Time: Discordance Rates Between Primary and Metastatic Breast Cancer. Anticancer Res
29: 1557-1562
[Abstract][Full Text]
Contractor, K. B., Aboagye, E. O.
(2009). Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET. JNM
50: 97S-105S
[Abstract][Full Text]
Kataja, V., Castiglione, M., On behalf of the ESMO Guidelines Working Group,
(2009). Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol
20: iv10-iv14
[Full Text]
Borczuk, A. C., Toonkel, R. L., Powell, C. A.
(2009). Genomics of Lung Cancer. Proc Am Thorac Soc
6: 152-158
[Abstract][Full Text]
Sparano, J. A., Moulder, S., Kazi, A., Coppola, D., Negassa, A., Vahdat, L., Li, T., Pellegrino, C., Fineberg, S., Munster, P., Malafa, M., Lee, D., Hoschander, S., Hopkins, U., Hershman, D., Wright, J. J., Kleer, C., Merajver, S., Sebti, S. M.
(2009). Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer. Clin. Cancer Res.
15: 2942-2948
[Abstract][Full Text]
Gong, Y., Sweet, W., Duh, Y.-J., Greenfield, L., Fang, Y., Zhao, J., Tarco, E., Symmans, W. F., Isola, J., Sneige, N.
(2009). Chromogenic In Situ Hybridization Is a Reliable Method for Detecting HER2 Gene Status in Breast Cancer: A Multicenter Study Using Conventional Scoring Criteria and the New ASCO/CAP Recommendations. Am J Clin Pathol
131: 490-497
[Abstract][Full Text]
Korn, E. L., Freidlin, B., Mooney, M.
(2009). Stopping or Reporting Early for Positive Results in Randomized Clinical Trials: The National Cancer Institute Cooperative Group Experience From 1990 to 2005. JCO
27: 1712-1721
[Abstract][Full Text]
Sargent, D.
(2009). Early Stopping for Benefit in National Cancer Institute-Sponsored Randomized Phase III Trials: The System Is Working. JCO
27: 1543-1544
[Full Text]
Lennon, S., Barton, C., Banken, L., Gianni, L., Marty, M., Baselga, J., Leyland-Jones, B.
(2009). Utility of Serum HER2 Extracellular Domain Assessment in Clinical Decision Making: Pooled Analysis of Four Trials of Trastuzumab in Metastatic Breast Cancer. JCO
27: 1685-1693
[Abstract][Full Text]
Leary, A. F., Hanna, W. M., van de Vijver, M. J., Penault-Llorca, F., Ruschoff, J., Osamura, R. Y., Bilous, M., Dowsett, M.
(2009). Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients. JCO
27: 1694-1705
[Abstract][Full Text]
Dolle, J. M., Daling, J. R., White, E., Brinton, L. A., Doody, D. R., Porter, P. L., Malone, K. E.
(2009). Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years. Cancer Epidemiol. Biomarkers Prev.
18: 1157-1166
[Abstract][Full Text]
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., Hortobagyi, G. N.
(2009). The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine. The Oncologist
14: 320-368
[Abstract][Full Text]
Houshmandi, S. S., Emnett, R. J., Giovannini, M., Gutmann, D. H.
(2009). The Neurofibromatosis 2 Protein, Merlin, Regulates Glial Cell Growth in an ErbB2- and Src-Dependent Manner. Mol. Cell. Biol.
29: 1472-1486
[Abstract][Full Text]
Ignatiadis, M., Desmedt, C., Sotiriou, C., de Azambuja, E., Piccart, M.
(2009). HER-2 as a Target for Breast Cancer Therapy. Clin. Cancer Res.
15: 1848-1852
[Full Text]
Sauter, G., Lee, J., Bartlett, J. M.S., Slamon, D. J., Press, M. F.
(2009). Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations. JCO
27: 1323-1333
[Abstract][Full Text]
Stokoe, C.
(2009). Adapting Practice in the Face of New Data. J Oncol Pract
5: 83-85
[Full Text]
Iverson, A. A., Gillett, C., Cane, P., Santini, C. D., Vess, T. M., Kam-Morgan, L., Wang, A., Eisenberg, M., Rowland, C. M., Hessling, J. J., Broder, S. E., Sninsky, J. J., Tutt, A., Anderson, S., Chang, S.-Y. P.
(2009). A Single-Tube Quantitative Assay for mRNA Levels of Hormonal and Growth Factor Receptors in Breast Cancer Specimens. J. Mol. Diagn.
11: 117-130
[Abstract][Full Text]
Anton, A., Ruiz, A., Segui, M. A., Calvo, L., Munoz, M., Lao, J., Sancho, F., Fernandez, L.
(2009). Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. Ann Oncol
20: 454-459
[Abstract][Full Text]
MIYAMOTO, S., FUKAMI, T., YAGI, H., KUROKI, M., YOTSUMOTO, F.
(2009). Potential for Molecularly Targeted Therapy against Epidermal Growth Factor Receptor Ligands. Anticancer Res
29: 823-830
[Abstract][Full Text]
Sargent, D., Sobrero, A., Grothey, A., O'Connell, M. J., Buyse, M., Andre, T., Zheng, Y., Green, E., Labianca, R., O'Callaghan, C., Seitz, J. F., Francini, G., Haller, D., Yothers, G., Goldberg, R., de Gramont, A.
(2009). Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials. JCO
27: 872-877
[Abstract][Full Text]
Russell, N. S., Kunkler, I. H., van Tienhoven, G., Canney, P. A., Thomas, J., Bartlett, J., van de Vijver, M. J., Belkacemi, Y., Yarnold, J. R., Barrett-Lee, P. J.
(2009). Postmastectomy Radiotherapy: Will the Selective Use of Postmastectomy Radiotherapy Study End the Debate?. JCO
27: 996-997
[Full Text]
Partridge, A. H., Winer, E. P.
(2009). Sharing Study Results With Trial Participants: Time for Action. JCO
27: 838-839
[Full Text]
Dawood, S., Broglio, K., Kau, S.-W., Green, M. C., Giordano, S. H., Meric-Bernstam, F., Buchholz, T. A., Albarracin, C., Yang, W. T., Hennessy, B. T.J., Hortobagyi, G. N., Gonzalez-Angulo, A. M.
(2009). Triple Receptor-Negative Breast Cancer: The Effect of Race on Response to Primary Systemic Treatment and Survival Outcomes. JCO
27: 220-226
[Abstract][Full Text]
Coxon, A., Bush, T., Saffran, D., Kaufman, S., Belmontes, B., Rex, K., Hughes, P., Caenepeel, S., Rottman, J. B., Tasker, A., Patel, V., Kendall, R., Radinsky, R., Polverino, A.
(2009). Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors. Clin. Cancer Res.
15: 110-118
[Abstract][Full Text]
Cortes, J., Di Cosimo, S., Climent, M. A., Cortes-Funes, H., Lluch, A., Gascon, P., Mayordomo, J. I., Gil, M., Benavides, M., Cirera, L., Ojeda, B., Rodriguez, C. A., Trigo, J. M., Vazquez, J., Regueiro, P., Dorado, J. F., Baselga, J., on behalf of the Spanish Breast Cancer Cooperative,
(2009). Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study. Clin. Cancer Res.
15: 307-314
[Abstract][Full Text]
Previous
